Business
Jaguar Health Announces Commitment to Move Forward with Exclusive Relationship with the Planned Dragon SPAC, which is Pursuing Listing on AIM Italia and Plans to Target Napo EU
Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler'
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in EuropeSAN FRANSISCO, CA / ACCESSWIRE / February 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) (\"Jaguar\" or the \"Company\") today announced that the Company is committed to moving forward with an exclusive relationship with the planned Dragon special purpose acquisition company (the \"Dragon SPAC\") and is supportive of the Dragon SPAC's intention for Napo EU, the anticipated subsidiary of the Company in Italy, to be the named target of the Dragon SPAC.As Jaguar announced yesterday, the Company has signed a Memorandum of Understanding (the \"MOU\") with Josh Mailman, the lead sponsor of the Dragon SPAC, which is pursuing listing on AIM Italia.\"Jaguar was previously in discussions with Andreea Porcelli, the founder and CEO of the planned Post Pandemic Recovery SPAC (the \"PPR SPAC\") regarding the listing of the PPR SPAC on AIM Italia and the potential merger of the PPR SPAC with Napo EU. However, we were not able to come to terms,\" stated Lisa Conte, Jaguar's founder, president, and CEO.\"Although I was also unable to come to terms with Ms. Porcelli regarding the PPR SPAC, I am happy to move forward with the Dragon SPAC - and the proposed direct business combination with Napo EU - in the best interest of all parties,\" Mailman said. \"I am the lead sponsor and providing funding for the proposed Dragon SPAC, and I am pleased to announce that we are in discussions with multiple global and Italian banks related to the anticipated listing of the Dragon SPAC on AIM Italia.\"Per the MOU, the Dragon SPAC has been granted exclusivity to negotiate and finalize the documentation for the contemplated merger transaction with Napo EU and to list the combined entity on AIM Italia.As previously announced, the Company is exploring the conditional marketing authorization regulatory pathway in Europe to support development and commercialization of crofelemer, the Company's novel proprietary drug, for the proposed indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a \"long-hauler\" COVID-19 recovery patient population in Europe (the \"COVID-related indication\"). The Company has engaged a regulatory agent in Eu...